| Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia (NCT02832037) | Boehringer Ingelheim | 2016-07-25 |
| Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness (NCT02845440) | Massachusetts General Hospital | 2016-07-14 |
| The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders (NCT03166098) | NYU Langone Health | 2016-07-05 |
| Repetitive Transcranial Magnetic Stimulation for the Treatment of Negative Symptoms in Schizophrenia Patients. (NCT02842034) | Shanghai Mental Health Center | 2016-07-01 |
| Validation of a Clinical Screening Grid for Syndromic Schizophrenia (NCT02746510) | Hôpital le Vinatier | 2016-07-01 |
| The Effects of tDCS on Auditory Hallucination, Insight, Neurocognitive Function and HRV in Patients With Schizophrenia (NCT03388554) | Tri-Service General Hospital (TSGH) | 2016-07-01 |
| A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics (NCT02824055) | Hoffmann-La Roche | 2016-06-27 |
| Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242 (NCT02824666) | Braeburn Pharmaceuticals | 2016-06-20 |
| Validation of a Scale to Evaluate the Perception of Oral Health in Patients With Schizophrenia (NCT02730832) | Centre Hospitalier Universitaire Dijon | 2016-06-20 |
| Discriminant Validity of the Multiple Errands Test in Schizophrenia (NCT02782091) | Assistance Publique - Hôpitaux de Paris | 2016-06-16 |
| Aripiprazole, Abilify Maintena Collaborative Clinical Protocol (NCT02717130) | Florida Atlantic University | 2016-06-08 |
| Virtual Reality Training for Social Skills in Schizophrenia (NCT03128099) | Vanderbilt University | 2016-06-01 |
| Comparison of the Effectiveness of Brexpiprazole With That of Risperidone (NCT02758067) | H. Lundbeck A/S | 2016-06-01 |
| A Phase 1 Safety Study in Adults With Schizophrenia (NCT02804568) | Alkermes, Inc. | 2016-06-01 |
| The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients (NCT03007303) | Dalian Seventh People's Hospital | 2016-06-01 |
| Cost-effectiveness of Interventions in First-episode Psychosis (NCT02916303) | Fundación Marques de Valdecilla | 2016-06-01 |
| Aerobic Exercise for the Improvement of Cognition and Enhancement of Recovery in Post-acute Schizophrenia (NCT03466112) | Ludwig-Maximilians - University of Munich | 2016-06-01 |
| The Effect Of Multiple Occupational Therapies On Functional Remission And Subjective Recovery For Schizophrenia (NCT06199817) | Ege University | 2016-06-01 |
| STIM'ZO : Examining tDCS as an add-on Treatment for Persistent Symptoms in Schizophrenia (NCT02744989) | Hospices Civils de Lyon | 2016-05-30 |
| Pharmacokinetics and Safety Studies of Esomeprazole Use in Schizophrenia Patients (NCT03333603) | National Taiwan University Hospital | 2016-05-23 |
| Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study (NCT02748694) | Neurocrine Biosciences | 2016-05-09 |
| Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia (NCT04352569) | Centre hospitalier de Ville-Evrard, France | 2016-05-03 |
| Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia (NCT02736474) | Shanghai Mental Health Center | 2016-05-01 |
| Siltuximab in Schizophrenia (NCT02796859) | Brian Miller | 2016-05-01 |
| Efficacy and Mechanisms of Change of an Emotion-oriented Version of Cognitive-behavioral Therapy for Psychosis (NCT02787135) | Philipps University Marburg | 2016-05-01 |
| Non-Invasive Direct Current Stimulation for Cognition in Schizophrenia (NCT02739347) | Baylor College of Medicine | 2016-05-01 |
| Somatic Comorbidities in Psychiatric Patients (NCT02773108) | Sveti Ivan Psychiatric Hospital | 2016-05-01 |
| A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation (NCT02713282) | Janssen-Cilag Ltd. | 2016-04-28 |
| Safety and Tolerability of Risperidone Implants (NCT02773576) | Braeburn Pharmaceuticals | 2016-04-01 |
| Evaluation of a Psychoeducation Program for Families Caregivers of Schizophrenic Patients : Randomized Study in Two Arms (NCT03000985) | Centre Hospitalier Charles Perrens, Bordeaux | 2016-04-01 |
| Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia (NCT02964923) | Xijing Hospital | 2016-04-01 |
| Response to Clozapine in Treatment Resistant Schizophrenia: A Longitudinal Magnetic Resonance Spectroscopy Study (NCT02714894) | Centre for Addiction and Mental Health | 2016-04-01 |
| Oxytocin and Social Decision Making in Schizophrenia (NCT04176835) | National Institute of Mental Health and Neuro Sciences, India | 2016-04-01 |
| The Gut Metagenome Research of Schizophrenia (NCT02708316) | First Affiliated Hospital Xi'an Jiaotong University | 2016-04-01 |
| Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia (NCT02717195) | H. Lundbeck A/S | 2016-04-01 |
| Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia (NCT02724917) | CoMentis | 2016-04-01 |
| The Potential Efficacy of the Chinese Health Improvement Profile- A Pilot Clustered Randomised Controlled Trial (NCT02453217) | Wai-Tong Chien | 2016-03-31 |
| A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia (NCT02720263) | Astellas Pharma Global Development, Inc. | 2016-03-28 |
| Motivational Negative Symptoms in Schizophrenia: Intervention and Biomarkers (NCT02386605) | VA Office of Research and Development | 2016-03-28 |
| Research Into Antipsychotic Discontinuation and Reduction Trial (NCT03559426) | University College, London | 2016-03-24 |
| A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study) (NCT02694328) | Alkermes, Inc. | 2016-03-02 |
| Disorder-tailored Transcranial Direct Current Stimulation (tDCS) of the Prefrontal Cortex (NCT02715128) | Ludwig-Maximilians - University of Munich | 2016-03-01 |
| Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System (NCT02722967) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2016-03-01 |
| A Trial of Cognitive Training in Schizophrenia (NCT02478827) | University of Calgary | 2016-03-01 |
| Efficacy of ISST in Schizophrenia (NCT02678858) | Heinrich-Heine University, Duesseldorf | 2016-03-01 |
| Tracking Outcomes in Psychosis (NCT02882204) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2016-03-01 |
| Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study (NCT02642029) | Mclean Hospital | 2016-02-18 |
| A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia (NCT02476708) | Yale University | 2016-02-11 |
| Adjunctive Vortioxetine in Schizophrenia (NCT02357797) | Northwell Health | 2016-02-01 |
| Positive Emotions Program for Schizophrenia (PEPS) (NCT02593058) | Institut et Haute Ecole de la Santé la Source | 2016-02-01 |
| 50 Hz vs. 25 Hz Magnetic Seizure Therapy for Schizophrenia (NCT03003156) | Shanghai Mental Health Center | 2016-02-01 |
| The Role of Personal Identity in Psychotic Symptoms: a Study With the Repertory Grid Technique (NCT03820362) | University of Barcelona | 2016-02-01 |
| Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia (NCT02661347) | Northwell Health | 2016-02-01 |
| PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia (NCT02687984) | Indivior Inc. | 2016-02-01 |
| rTMS Treatment for Positive and Negative Symptoms of Schizophrenia (NCT03413527) | St. Joseph's Healthcare Hamilton | 2016-02-01 |
| Remote Monitoring and Support for Patients With Schizophrenia, Schizoaffective or Bipolar Disorder on Adherence (NCT02665611) | Assuta Hospital Systems | 2016-02-01 |
| Cannabidiol Treatment in Patients With Early Psychosis (NCT02504151) | Yale University | 2016-01-28 |
| Reducing Cardiovascular Risk in Adults With Serious Mental Illness (NCT02451670) | HealthPartners Institute | 2016-01-20 |
| A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia (NCT02669758) | Alkermes, Inc. | 2016-01-20 |
| Virtual Rehabilitation for the Treatment of Motivational Deficits in Schizophrenia (NCT02709733) | Centre for Addiction and Mental Health | 2016-01-01 |
| Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment With Antipsychotics (NCT02573168) | St. Joseph's Healthcare Hamilton | 2016-01-01 |
| Skills Training to Enhance Vocational Outcomes in Veterans With Serious Mental Illness (NCT02663349) | Minneapolis Veterans Affairs Medical Center | 2016-01-01 |
| Role Functioning Changes NOS (NCT02505022) | Northwestern University | 2016-01-01 |
| Participatory Video as a Recovery-Oriented Intervention in Early Psychosis (NCT02360566) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2016-01-01 |
| Aerobic Exercise for Cognition in Schizophrenia (NCT02621983) | VA Office of Research and Development | 2016-01-01 |
| Target Engagement of the Early Auditory Processing Network by Transcranial Direct Current Stimulation (tDCS) (NCT02620267) | VA Greater Los Angeles Healthcare System | 2015-12-15 |
| Early and Short Psycho-educational Lifestyle Intervention (NCT02657941) | Hôpital le Vinatier | 2015-12-09 |
| Video as a Tool to Improve Insight in Schizophrenia (NCT02664129) | University Hospital, Montpellier | 2015-12-08 |
| A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients (NCT02088060) | Central Institute of Mental Health, Mannheim | 2015-12-08 |
| Social Cognitive Assessment in Autism and Schizophrenia (NCT02660775) | Hôpital le Vinatier | 2015-12-04 |
| Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophreniform Disorder (NCT03848234) | Tangent Data | 2015-12-04 |
| A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder (NCT02636842) | Alkermes, Inc. | 2015-12-01 |
| Transcranial Direct Current Stimulation (tDCS) as a Treatment for Cognitive Deficits in Schizophrenic (NCT02748083) | Shanghai Mental Health Center | 2015-12-01 |
| A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study) (NCT02634346) | Alkermes, Inc. | 2015-12-01 |
| A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia (NCT02634320) | Alkermes, Inc. | 2015-12-01 |
| Emotion Endophenotypes in Schizophrenia (NCT02834208) | Assistance Publique Hopitaux De Marseille | 2015-12-01 |
| Carnosine and Cognitive Training in Schizophrenia (NCT02686697) | Abraham Reichenberg | 2015-12-01 |
| Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia (NCT02614586) | Takeda | 2015-12-01 |
| Long-Term Exercise Training Therapy Versus Usual Care in Patients With Schizophrenia (NCT02743143) | St. Olavs Hospital | 2015-12-01 |
| Promoting Physical Activity in People With Schizophrenia. (NCT03514212) | University of Edinburgh | 2015-11-24 |
| Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness (NCT02594696) | Massachusetts General Hospital | 2015-11-09 |
| Multi-center Imaging Genetics Studies in China (NCT02681822) | Tianjin Medical University General Hospital | 2015-11-01 |
| Development of a Mobile System for Self-management of Schizophrenia (SOS) (NCT01969500) | Dartmouth-Hitchcock Medical Center | 2015-11-01 |
| Perception of Facial Emotions in Schizophrenia and 22q11 Deletion Syndrome (NCT02634671) | Hôpital le Vinatier | 2015-11-01 |
| The Neural Bases of Early Visual and Auditory Processing and Emotion Recognition Deficits in Schizophrenia (NCT02588014) | Shalvata Mental Health Center | 2015-11-01 |
| Comparative Bioavailability Study of Aripiprazole 10 mg Oral Soluble Film vs Abilify® 10 mg Tablet in Healthy Volunteers (NCT02501109) | CMG Pharmaceutical Co. Ltd | 2015-10-01 |
| Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant (NCT02658357) | Braeburn Pharmaceuticals | 2015-10-01 |
| Efficacy and Mechanisms of Transcranial Direct Current Stimulation (tDCS) - Effects on Working Memory in Schizophrenia (NCT02823639) | University Hospital Tuebingen | 2015-10-01 |
| Modified Psychodynamic Psychotherapy for Patients With Schizophrenia (NCT02576613) | Charite University, Berlin, Germany | 2015-10-01 |
| Metacognitive Intervention for Individuals With Severe Mental Disorders (NCT05556941) | University of Haifa | 2015-10-01 |
| Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine (NCT02304432) | Mclean Hospital | 2015-09-27 |
| Psychiatric Disorders and Electrophysiological Markers (NCT02329119) | Assistance Publique Hopitaux De Marseille | 2015-09-01 |
| Understanding and Helping Families: Parents With Psychosis (NCT02622048) | University of Manchester | 2015-09-01 |
| RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia) (NCT02160249) | London School of Hygiene and Tropical Medicine | 2015-09-01 |
| Safety, Blood Levels and Effects of AUT00206 (NCT02589262) | Autifony Therapeutics Limited | 2015-09-01 |
| The Significance of Deviation in Time From the 12-hour Standard Serum-clozapine Monitoring. (NCT02625103) | Anders Fink-Jensen, MD, DMSci | 2015-09-01 |
| Coronary Artery Disease in Patients Suffering From Schizophrenia (NCT02885792) | Aalborg Psychiatric Hospital | 2015-09-01 |
| Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia (NCT02477670) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2015-09-01 |
| Music Therapy Towards Schizophrenia, Negative Symptoms (NCT02942459) | Inge Nygaard Pedersen | 2015-09-01 |
| Bifrontal and Bitemporal Electroconvulsive Therapy (ECT) in Treatment of Patients With Schizophrenia (NCT02511509) | Medical University of Lodz | 2015-09-01 |